Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.91 |
| ▸ | AXL | P30530 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ULK1 | O75385 | 1/20 | 0.44 |
| ▸ | BCL6 | P41182 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22866360 | 0.97 | KMT2A (0.97) | KMT2AAXLALDH1A1L3MBTL1ULK1 | |
| SCHEMBL657615 | 0.95 | KMT2A (1.00) | KMT2AAXLALDH1A1L3MBTL1ULK1 | |
| SCHEMBL1937922 | 0.93 | KMT2A (0.84) | KMT2AAXLALDH1A1L3MBTL1ULK1 | |
| SCHEMBL16199054 | 0.87 | KMT2A (0.70) | KMT2AAXLALDH1A1L3MBTL1ADORA3 | |
| SCHEMBL22247489 | 0.87 | KMT2A (0.70) | KMT2AAXLALDH1A1L3MBTL1BCL6 | |
| SCHEMBL2142331 | 0.87 | KMT2A (0.70) | KMT2AAXLALDH1A1L3MBTL1ADORA3 | |
| SCHEMBL9977770 | 0.87 | KMT2A (0.70) | KMT2AAXLALDH1A1L3MBTL1ADORA3 | |
| SCHEMBL2126173 | 0.87 | KMT2A (0.70) | KMT2AAXLALDH1A1L3MBTL1ADORA3 | |
| SCHEMBL17518644 | 0.87 | KMT2A (0.70) | KMT2AAXLALDH1A1L3MBTL1ADORA3 | |
| SCHEMBL10008381 | 0.87 | KMT2A (0.70) | KMT2AAXLALDH1A1L3MBTL1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557806-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8158621-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20110245242-A1 | Heterocyclically Substituted Anilinopyrimides | BAYER CROPSCIENCE AG (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245284-A1 | Alkoxy- and Alkylthio-Substituted Anilinopyrimidines | BAYER CROPSCIENCE AG (DE) | 2011-10-06 | — | — | US | disclosed |
| EP-2331512-A1 | ALKOXY-SUBSTITUTED AND ALKYLTHIO-SUBSTITUTED ANILINOPYRIMIDINES | Bayer CropScience AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| US-7825116-B2 | -(2-Aminopyrid-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for immunoglobulins IgE and IgG antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7820648-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2010-10-26 | — | — | US | disclosed |
| US-7812029-B1 | such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| WO-2010025833-A1 | ALKOXY-SUBSTITUTED AND ALKYLTHIO-SUBSTITUTED ANILINOPYRIMIDINES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | disclosed |
| US-7517886-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080234303-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| EP-1966207-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007072158-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245284-A1 | Alkoxy- and Alkylthio-Substituted Anilinopyrimidines | HAX1, AGPS, PYM1 | KMT2A 1008/4885AXL 251/4885ALDH1A1 579/4885 |
| US-20080234303-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | CCNB1, TYMS, CCNA1 | KMT2A 1056/4885AXL 3024/4885ALDH1A1 714/4885 |
| US-20110245242-A1 | Heterocyclically Substituted Anilinopyrimides | H1-10, POLL, PPM1D | KMT2A 1011/4885AXL 840/4885ALDH1A1 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.